Physician profile
Thomas Pappas
NPI 1164474417
$3,127.57
in general payments reported to CMS, 2019-2025
23 companies · $774 in 2025
The $774 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $47.72 · 2021: $466 · 2022: $207 · 2023: $613 · 2024: $680 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $561.45 | 2020-2024 | Xarelto |
| Medtronic, INC. | $526.50 | 2021-2024 | Onyx Frontier, Symplicity G3 |
| Shockwave Medical, INC | $264.13 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $253.70 | 2022-2025 | Perclose Proglide, Perclose Prostyle, Esprit |
| E.R. Squibb & Sons, L.L.C. | $242.83 | 2023-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $167.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Vascular, INC. | $159.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $146.40 | 2023-2025 | |
| Pfizer INC. | $111.96 | 2019-2025 | |
| Cvrx, INC. | $98.93 | 2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $88.82 | 2020-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $77.53 | 2022-2023 | Assure Wcd |
| Philips North America LLC | $68.39 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Boston Scientific Corporation | $68.16 | 2019 | |
| Abiomed | $66.62 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $44.80 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $38.09 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.92 | 2025 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.81 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $20.00 | 2019 | |
| Althera Pharmaceuticals LLC | $18.75 | 2021 | |
| Penumbra, INC. | $16.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.